MINIject® Implant
is used on patients who have been diagnosed with open angle glaucoma.
MINIject® the latest glaucoma treatment
is now available for patients at Harley Street Eye Hospital
Why is the MINIject® used?
The MINIject® is used to reduce intraocular pressure (IOP) by channelling aqueous humour out of the anterior chamber to the supraciliary space, thus enhancing physiological uvescleral outflow.
MINIject®combines the distinctive porous structure of its proprietary STAR material with the power offered by the supraciliary space.
As a result, it is designed to enhance natural fluid outflow, reducing intraocular pressure (IOP) and the need for medication, while bio-integrating with surrounding tissue, limiting inflammation, fibrosis and subsequent complications.
Glaucoma is a progressive disease affecting over 100 million people globally, of which primary open-angle glaucoma is the most common form. IOP reduction, through medication or surgery, helps delay disease progression.
Medication is generally the first line treatment, but the progressive addition of multiple drops can burden patients with side effects, compliance challenges and costs.
MIGS is the most promising and fastest-growing glaucoma therapy due to its enhanced safety profile. MINIject is potentially best-in-class for its promising long-term efficacy and safety.
How does the MINIject® work?
MINIject® is an innovative MIGS device for patients with primary open-angle glaucoma. MINIject® combines the distinctive porous structure of its proprietary STAR material with the power offered by the supraciliary space.
As a result, it is designed to enhance natural fluid outflow, reducing intraocular pressure (IOP) and the need for medication, while bio-integrating with surrounding tissue, limiting inflammation, fibrosis and subsequent complications.